Исланд - Исландски - LYFJASTOFNUN (Icelandic Medicines Agency)

medical valley invest ab - losartanum kalíum - filmuhúðuð tafla - 100 mg

Исланд - Исландски - LYFJASTOFNUN (Icelandic Medicines Agency)

medical valley invest ab - losartanum kalíum - filmuhúðuð tafla - 50 mg

Исланд - Исландски - LYFJASTOFNUN (Icelandic Medicines Agency)

krka sverige ab - losartanum kalíum - filmuhúðuð tafla - 100 mg

Исланд - Исландски - LYFJASTOFNUN (Icelandic Medicines Agency)

krka sverige ab - losartanum kalíum - filmuhúðuð tafla - 12,5 mg

Исланд - Исландски - LYFJASTOFNUN (Icelandic Medicines Agency)

krka sverige ab - losartanum kalíum - filmuhúðuð tafla - 50 mg

Европска Унија - Исландски - EMA (European Medicines Agency)

janssen-cilag international n.v. - abiraterone acetate, niraparib tosilate monohydrate - stækkun Æxli, gelding-Þola - Æxlishemjandi lyf - treatment of adult patients with prostate cancer.

Европска Унија - Исландски - EMA (European Medicines Agency)

stemline therapeutics b.v. - elacestrant - brjóstakrabbamein - innkirtla meðferð - orserdu monotherapy is indicated for the treatment of postmenopausal women, and men, with estrogen receptor (er) positive, her2-negative, locally advanced or metastatic breast cancer with an activating esr1 mutation who have disease progression following at least one line of endocrine therapy including a cdk 4/6 inhibitor.

Европска Унија - Исландски - EMA (European Medicines Agency)

daiichi sankyo europe gmbh - quizartinib dihydrochloride - kyrningahvítblæði, mergbólga - antineoplastic agents, protein kinase inhibitors - vanflyta is indicated in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, followed by vanflyta single-agent maintenance therapy for adult patients with newly diagnosed acute myeloid leukaemia (aml) that is flt3-itd positive.

Европска Унија - Исландски - EMA (European Medicines Agency)

novartis europharm limited - tislelizumab - esophageal squamous cell carcinoma - Æxlishemjandi lyf - oesophageal squamous cell carcinoma (oscc) tevimbra as monotherapy is indicated for the treatment of adult patients with unresectable, locally advanced or metastatic oesophageal squamous cell carcinoma after prior platinum-based chemotherapy.

Европска Унија - Исландски - EMA (European Medicines Agency)

bayer ag  - octocog alfa - hemophilia a - antihemorrhagics - meðferð og fyrirbyggjandi blæðingar hjá sjúklingum með dreyrasýki a (meðfæddan þáttur viii-skortur). Þetta undirbúningur inniheldur ekki von willebrand þáttur og er því ekki fram í von willebrand er sjúkdómur.